

Eisai brings Novartis executive on oncology board

23 May 2019 | News

Eisai Inc. Announces the Appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group



Eisai Inc., the U.S. pharmaceutical subsidiary of Japan headquartered Eisai Co., Ltd., has announced the immediate appointment of Dr. Luca Dezzani as Vice President, U.S. Medical Affairs, Oncology Business Group.

He will be responsible for creating the Medical Affairs strategy for the company's oncology portfolio of both commercialized and investigational products in the United States. He will also oversee Eisai's Health Economics & Outcomes Research (HEOR), Medical Science Liaisons (MSL) and Medical Information & Education teams.

Dr. Dezzani joins Eisai from Novartis Oncology, where he held senior medical roles in Europe and the United States. His experience ranges across multiple disease areas in hematology and oncology, as well as rare diseases. He obtained his Medical Doctor (M.D.) degree from the University of Pavia in Italy, where he also completed his residency in internal medicine with specialized training in hematology and oncology.